At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 89 enrolled
Drug / intervention
latanoprost +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation
In Brief
A Phase 4 clinical trial evaluating latanoprost, bimatoprost, and 1 other intervention for Glaucoma and Application Site Pigmentation Changes. Completed, enrolled 89 participants across 2 sites.
Detailed Summary
The purpose of this study is to study changes in skin color that may be caused by using one of the three eye medicines: Xalatan, Travatan or Lumigan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Application Site Pigmentation Changes
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedJun 2008
Primary CompletionApr 2011
TodayJul 2026
First PostedJun 26, 2008
Enrollment StartMar 1, 2008
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 18.0 years ago
Interventions
latanoprostdrug
Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year
bimatoprostdrug
Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year
travoprostdrug
Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year